ABSTRACT
Primary actinomycotic endocarditis is extremely rare. The author reported a case who suffered from endocarditis due to Actinomyces georgiae which the portal of entry for the organism could not be determined The author also reviewed the literature which described similar conditions. In addition, to the author's knowledge, there have been no reported cases of actinomyces georgiae endocarditis. Thus, this is the first report in the world. Clinical features of this rare condition are indistinguishable from other bacterial endocarditis. Actinomyces spp. is usually susceptible to a wide range of antibiotics, and endocarditis caused by this genus needs a prolonged course of antimicrobial treatment. However the optimal duration of therapy is still unknown. Prognosis is good with early detection and proper management.
Subject(s)
Actinomyces/isolation & purification , Actinomycosis/diagnosis , Amoxicillin/therapeutic use , Ampicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Antihypertensive Agents/therapeutic use , Ceftriaxone/therapeutic use , Enalapril/therapeutic use , Endocarditis, Bacterial/diagnosis , Humans , Male , Middle Aged , Penicillin G/therapeutic useABSTRACT
Chromobacterium violaceum infection in humans is a rare tropical and subtropical disease. The awareness of this organism is limited in spite its ubiquitous distribution. Several cases have been reported from Southeast Asia. A localized infection followed by an overwhelming septicemia and metastatic lesions is the usual pattern of this illness. Optimal antimicrobial treatment and duration are unknown. Consequently, the outcome is usually fatal. The study reported two patients who suffered from fulminant Chromobacterium violaceum sepsis with disseminated infection, and reviews the literature for cases reported from Southeast Asia.